Journal
Journal of Medical Economics
Publication Date
12-1-2026
Volume
29
Issue
1
First Page
594
Last Page
608
Document Type
Open Access Publication
DOI
10.1080/13696998.2026.2633930
Rights and Permissions
Qian F, Bensimon AG, Tzontcheva A, Benjamin K, Uppaluri R, Adkins D, Johnson G, Fernan C, Zheng D, Tang Y, Chafamo B, Muston D. Economic evaluation of perioperative pembrolizumab plus standard of care as treatment for resectable locally advanced head and neck squamous cell carcinoma in the United States. J Med Econ. 2026 Dec;29(1):594-608. doi: 10.1080/13696998.2026.2633930. Copyright 2026 Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc., Rahway, NJ, USA. Published by Informa UK Limited, trading as Taylor & Francis GroupThis is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives License (http://creativecommons.org/licenses/by-nc-nd/4.0/), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited,and is not altered, transformed, or built upon in any way. The terms on which this article has been published allow the posting of the Accepted Manuscript in arepository by the author(s) or with their consent.
Recommended Citation
Qian, Feng; Bensimon, Arielle G; Tzontcheva, Anjela; Benjamin, Kimberly; Uppaluri, Ravindra; Adkins, Douglas; Johnson, Geoffrey; Fernan, Catherine; Zheng, Dandan; Tang, Yuexin; Chafamo, Biruk; and Muston, Dominic, "Economic evaluation of perioperative pembrolizumab plus standard of care as treatment for resectable locally advanced head and neck squamous cell carcinoma in the United States." Journal of Medical Economics. 29, 1. 594 - 608. (2026).
https://digitalcommons.wustl.edu/oa_4/6467
Department
ICTS (Institute of Clinical and Translational Sciences)
Additional Links
Supplemental material is available for this article at publisher site.
